Answers are grounded in this paper and cite their sources.
Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and mortality, particularly in low- and middle-income countries, yet no therapy targets its underlying autoimmune mechanisms. We combined transcriptomic analyses of rheumatic mitral valves tissues with a translational approach. Using a panel of 750 mRNAs, we found a marked upregulation of B-cell-related pathways, including CD20-associated and multiple immunoglobulin genes, supporting a pathogenic role of B cells in RHD. We therefore evaluated an anti-CD20 B-cell depleting monoclonal antibody (Rituximab), in a feasibility study in children with RHD, in Dakar, Senegal. Treatment was well tolerated, and in the following RCT first year preliminary safety analysis asked by the ethical committee, children who received rituximab showed a decrease in anti-streptolysin O titers and clinical improvement compared to controls. This proof-of-concept reveals B cells as a therapeutic target and suggests that an anti-CD20 agent may represent a potential disease-modifying therapy for RHD.
No takes yet. Share an insight, caveat, or question.
Jouven et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: